95% male) who received care in fiscal years 2017 to 2023, 12% received at least one prescription for a GLP-1 RA, most commonly dulaglutide, semaglutide, or tirzepatide (which is also an agonist of the glucose-dependent insulinotropic polypeptide [GIP] receptor)
Appetite suppression
A.KenyonN.KamimuraS.KhaibullinaA.et al
Gastrointestinal safety of semaglutide and tirzepatide vs placebo in obese individuals without diabetes: A systematic review and meta-analysis
News Release March 28, 2023 Expanded Flaxseed Testing by ConsumerLab Reveals More Cadmium Contamination Several Quality Products Also Identified White Plains, New York, March 28, 2023 Due to concerning levels of cadmium ConsumerLab discovered in its tests of flaxseed products in January 2023, ConsumerLab recently purchased and tested seven additional whole and ground flaxseed products
Conclusion Learning how to give GLP-1 injection is a foundational skill for anyone taking control of their metabolic health through modern medication
